The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 1,036 |
| Net loss | -40,666 | -76,913 |
| Depreciation | 523 | 1,036 |
| Stock-based compensation | 8,085 | 16,792 |
| Accretion of discount on marketable securities, net | 2,056 | 4,126 |
| Amortization of right-of-use asset | 47 | 85 |
| Prepaid expenses and other assets | 1,298 | 3,950 |
| Accounts payable | -2,132 | 2,707 |
| Accrued compensation | 2,362 | -4,420 |
| Accrued other expenses and other liabilities | 548 | -1,293 |
| Lease liability | -189 | -366 |
| Net cash used in operating activities | -34,776 | -70,448 |
| Maturities of marketable securities | - | 229,118 |
| Purchases of marketable securities | 66,999 | 385,942 |
| Sales of marketable securities | 51,452 | 38,650 |
| Maturities of marketable securities | 319,120 | - |
| Purchases of property and equipment | 183 | 94 |
| Net cash used in investing activities | 35,716 | -118,268 |
| Proceeds from issuance of common stock, net of offering costs | 0 | 187,362 |
| Exercise of stock options | 1,659 | 2,494 |
| Proceeds from employee stock purchase plan | 0 | 598 |
| Net cash provided by financing activities | 1,659 | 190,454 |
| Net change in cash and cash equivalents | 2,599 | 1,738 |
| Cash and cash equivalents at beginning of period | 41,666 | - |
| Cash and cash equivalents at end of period | 46,003 | - |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)